PTK2B and chronic myelogenous leukemia, BCR-ABL1 positive: Subsequent to exposure to 1.0 μmol/l imatinib for 48 h, BCR-ABL protein levels and PTK activity were assessed in the CD34+ cells from patients with CML in the megakaryocytic and myeloid crisis phases.